Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes

Neurology

Volumn 76, Issue 12, 2011, Pages 1078-1084

  Caselli, R J ^a,b,h   Dueck, A C ^b,h   Locke, D E C ^b,h   Sabbagh, M N ^c,h   Ahern, G L ^d,h   Rapcsak, S Z ^d,h,i   Baxter, L C ^e,h   Yaari, R ^f,h   Woodruff, B K ^b,h   Hoffman Snyder, C ^b,h   Rademakers, R ^g,h   Findley, S ^b,h   Reiman, E M ^d,f,h  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e BARROW NEUROLOGICAL INSTITUTE   (United States)

^f BANNER ALZHEIMER S INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

^h ARIZONA ALZHEIMER S CONSORTIUM   (United States)

ⁱ SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONG TERM MEMORY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RISK FACTOR;

EID: 79953167888     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318211c3ae     Document Type: Article

References (40)

1. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63: 1187-1192. (Pubitemid 39350015)
2. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175-1181. (Pubitemid 34411860)
3. Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009;66:343-348.
4. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010;19: 465-480.
5. Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009;40:3180-3185.
6. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64:494-500. (Pubitemid 40189869)
7. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006;67:1960-1965. (Pubitemid 44967371)
8. Morris MC, Scherr PA, Hebert LE, et al. Association between blood pressure and cognitive function in a biracial community population of older persons. Neuroepidemiology 2002;21:123-130. (Pubitemid 34507653)
9. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997;277:813-817. (Pubitemid 27111317)
10. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer's disease pathology. Neurology 2004;62: 1148-1155. (Pubitemid 38456510)
11. Llewellyn DJ, Lang IA, Xie J, Huppert FA, Melzer D, Langa KM. Framingham stroke risk profile and poor cognitive function: a population-based study. BMC Neurol 2008;8:12.
12. Newman AB, Arnold AM, Sachs MC, et al. Long-term function in an older cohort-the cardiovascular health all stars study. J Am Geriatr Soc 2009;57:432-440.
13. Areosa SA, Grimley EV. Effect of treatment of type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002;4: CD003804.
14. McGuiness B, Todd S, Passmore, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009;4:CD004034.
15. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009;15:CD003160.
16. Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI. Stroke Epub 2010.
17. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc 2009;57:797-805.
18. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer's disease. Neurology 2009;73:674-680.
19. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele-4 with late onset familial and sporadic Alzheimer's disease. Neurology 1993;43: 1467-1472.
20. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009;361:255-263.
21. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE-4 in modulating the effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;281:40-46.
22. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Washington, DC: American Psychiatric Association; 1994.
25. Rey A. l'Examen Clinique en Psychologie. Paris: Presses Universitaires 1964.
26. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572. (Pubitemid 37430158)
28. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26(suppl 1):S5-S20.
29. Ware JH, Dockery DW, Louis TA, XU X, Ferris BG, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiology 1990;132:685-700. (Pubitemid 20344536)
30. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis (Section 15.4). Hoboken: John Wiley & Sons, Inc.; 2004.
31. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278:136-140. (Pubitemid 27287671)
32. Gromadzka G, Baranska-Gieruszczak M, Sarzynska-Dlugosz I, Cielielska A, Czlonkowska A. The APOE polymorphism and 1-year outcome in ischemic stroke: genotype-gender interaction. Acta Neurol Scand 2007; 116:392-398. (Pubitemid 350045495)
33. Heyer EJ, Wilson DA, Sahlein DH, et al. APOE-epsilon4 predisposes to cognitive dysfunction following uncomplicated carotid endarterectomy. Neurology 2010;65:1759-1763.
34. Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:1329-1335. (Pubitemid 44851989)
35. Hopkins RO, Weaver LK, Valentine KJ, Mower C, Churchill S, Carlquist J. Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric oxygen treatment. Am J Respir Crit Care Med 2007;176: 1001-1006. (Pubitemid 350127844)
36. Olsson Y, Brun A, Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand Suppl 1996;168:31-38.
37. O'Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002;59:321-326. (Pubitemid 34857922)
38. DeCarli C, Miller BL, Swan GE, et al. Predictors of brain morphology for the men of the NHBLI twin study. Stroke 1999;30:529-536. (Pubitemid 29115387)
39. Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology 2008;7:246-255. (Pubitemid 351215983)
40. Schneider JA, Arvatanakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200-208.